Amgen and pharmacy benefit manager (PBM) Abarca this week announced that they have entered into an outcomes-based contract for brand-name etanercept, Enbrel.
Amgen and pharmacy benefit manager (PBM) Abarca this week announced that they have entered into an outcomes-based contract for brand-name etanercept, Enbrel.
Under the terms of the agreement, Agmen will provide rebates to the PBM’s clients for members of commercial health plans who start etanercept to treat rheumatoid arthritis (RA), but who discontinue after 3 months of treatment.
Abarca will use its software that tracks utilization in real-time in order to generate the information necessary to track patient discontinuation and trigger rebates from the drug maker.
"This is a win for all parties," Jason Borschow, president and chief executive officer of Abarca, said in a statement. "It will provide Amgen valuable information about how Enbrel is utilized, it will lower costs for plans, and it will bring additional benefits to our healthcare system."
While anti—tumor necrosis factor (anti-TNF) therapies like etanercept can be highly effective treatments for RA, approximately 20% to 40% of patients who start an anti-TNF drug fail to achieve and adequate response to their therapy. These patients may go on to cycle to another anti-TNF drug or change treatment to a biologic with a different mechanism of action altogether, and that process can be a costly one. An outcomes-based contract like the one struck between Amgen and Abarca may help shield PBM clients from some of those costs.
The timing of the deal, which could make the drug an appealing choice for those starting anti-TNF therapy, comes as biosimilar challengers to Enbrel are seeking to enter the market with their approved products.
Sandoz, which developed the biosimilar etanercept Erelzi, was recently delivered a blow when the United States District Court for the District of New Jersey has ruled in favor of Amgen in a long-running patent litigation concerning the biosimilar. Opening briefs have been filed in the US Court of Appeals concerning the case, however, and Sandoz executives have indicated that the company remains dedicated to brining the biosimilar to market as soon as possible. Another biosimilar, Samsung Bioepis’ Eticovo, is also FDA-approved but has yet to launch.
Amgen has previously entered into outcomes-based contracting for etanercept; in 2017, Amgen and Harvard Pilgrim Health Care struck a deal in which patients receiving the drug were scored on criteria including compliance, added drugs, and dose escalation. Patient scores that did not meet a prespecified threshold resulted in lower reimbursement for Amgen.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.